Tabrecta、INC280、Rahika、卡马替尼、LuciCapma(Capmatinib)

Capmatinib

Another Name
Tabrecta、INC280、Rahika、卡马替尼、LuciCapma(Capmatinib)
Indications
Capmatinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).
Reg No
07 L 0996/23
Inspection No
1765-23
dosage form:tablets
Specs:200mg*60 tablets
Indate:24 months
Date：2024-8-31 Views：1049
Drug Info

COMPOSITION:

Each film-coated Lucicapma tablet contains: Capmatinib HCL (anhydrous) 235.40 mg equivalent to Capmatinib 200mg

INDICATION:

LuciCapma is for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).

DOSAGE AND USE:

Recommended dosage: 400 mg orally twice daily with or without food.

Tablets should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 20°C to 25°C

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of the reach of Children. Do not administered LuciCapma in Pregnancy and Lactation patient treatment.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/capmatinib/

Related News